Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Canagliflozin and Brusatol Synergize against LKB1-KEAP1 Co-Mutant NSCLC through AKT Suppression.

International journal of biological sciences - 1 Jan 2026

Chen Yiguan, Gao Xiang-Zheng, Rong Dade, Gao Liangliang, Tang Mingzhu, Lu Guang, Ling Zhi-Qiang, Shen Han-Ming

Abstract excerpt

Liver kinase B1 (LKB1, encoded by STK11) is an important tumour suppressor, with approximately 30% of non-small cell lung cancer (NSCLC) patients harbouring LKB1 mutations. Our previous work showed that LKB1-mutant NSCLC cells are sensitive to glucose starvation, suggesting that suppression of glucose metabolism may serve as a potential therapeutic strategy for NSCLC patients with LKB1 mutation. In this study, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Apoptosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Kelch-Like ECH-Associated Protein 1

Share to Mice, Nude

Share to NF-E2-Related Factor 2

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins c-akt

Source

Open in PubMed Open full text

Identifiers

PMID: 42157939
DOI: 10.7150/ijbs.124757
PMCID: PMC13182243

Genes

KEAP1
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Canagliflozin and Brusatol Synergize against LKB1-KEAP1 Co-Mutant NSCLC through AKT Suppression.PMID 42157939Read ↗

Synthetic lethality targeting LKB1 mutant and EGFR wild type human non-small cell lung cancer cells by glucose starvation and SGLT2 inhibitionSemantic proximity Read ↗

Unravelling the connection between metabolism and tumorigenesis through studies of the liver kinase B1 tumour suppressorSemantic proximity Read ↗

SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma.Semantic proximity Read ↗

SGLT2 Inhibition Induces Autophagic Flux Blockade and Sensitizes Pancreatic Cancer to EGFR-Targeted TherapySemantic proximity Read ↗

Insights into targeting LKB1 in tumorigenesisSemantic proximity Read ↗

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.Semantic proximity Read ↗

Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer.Semantic proximity Read ↗

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancerSemantic proximity Read ↗

Targeting AMPK for Cancer Therapy: Metabolic Reprogramming as a Therapeutic StrategySemantic proximity Read ↗

LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRASG12C + MCL-1 blockadeSemantic proximity Read ↗

Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approachSemantic proximity Read ↗

Tumor loss-of-function mutations in STK11/LKB1 induce cachexia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.